UiPath (NYSE:PATH) PT Raised to $15.00

UiPath (NYSE:PATH) had its target price boosted by equities research analysts at Barclays from $14.00 to $15.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has an “equal weight” rating on the healthcare company’s stock. Barclays‘s target price would indicate a potential upside of 25.31% from the stock’s previous close.

A number of other research firms also recently weighed in on PATH. Wells Fargo & Company raised their price target on UiPath from $14.00 to $15.00 and gave the company an “equal weight” rating in a research report on Friday. KeyCorp reissued a “sector weight” rating on shares of UiPath in a report on Thursday, May 30th. Mizuho cut their target price on UiPath from $25.00 to $14.00 and set a “neutral” rating for the company in a research note on Thursday, May 30th. TD Cowen reissued a “hold” rating and set a $17.00 price target (down from $28.00) on shares of UiPath in a research note on Thursday, May 30th. Finally, BMO Capital Markets upped their price objective on shares of UiPath from $14.00 to $15.00 and gave the company a “market perform” rating in a research note on Friday. Sixteen analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $17.71.

UiPath Trading Down 6.0 %

Shares of PATH opened at $11.97 on Friday. UiPath has a 12-month low of $10.37 and a 12-month high of $27.87. The company has a market cap of $6.86 billion, a PE ratio of -74.81 and a beta of 0.87. The stock has a 50-day moving average price of $12.20 and a 200-day moving average price of $16.66.

UiPath (NYSE:PATH) last announced its earnings results on Thursday, September 5th. The healthcare company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.01. The business had revenue of $316.00 million during the quarter, compared to analyst estimates of $303.69 million. UiPath had a negative net margin of 6.41% and a negative return on equity of 2.97%. UiPath’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.09) earnings per share. As a group, analysts predict that UiPath will post -0.22 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PATH. Mark Sheptoff Financial Planning LLC bought a new stake in shares of UiPath in the 4th quarter worth approximately $25,000. ORG Partners LLC boosted its holdings in UiPath by 875.6% in the first quarter. ORG Partners LLC now owns 1,239 shares of the healthcare company’s stock valued at $27,000 after acquiring an additional 1,112 shares in the last quarter. Hantz Financial Services Inc. purchased a new position in UiPath during the 2nd quarter valued at $28,000. Redwood Wealth Management Group LLC bought a new position in UiPath in the 2nd quarter worth $43,000. Finally, Lindbrook Capital LLC raised its holdings in UiPath by 46.0% in the 1st quarter. Lindbrook Capital LLC now owns 2,027 shares of the healthcare company’s stock worth $46,000 after purchasing an additional 639 shares in the last quarter. Institutional investors own 62.50% of the company’s stock.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.